Skip to content

Clinical outcomes of pharmacokinetic and pharmacodynamic meropenem dosing in critically ill patients with sepsis or septic shock

Clinical outcomes of pharmacokinetic and pharmacodynamic meropenem dosing in critically ill patients with sepsis or septic shock

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20220106001
Enrollment
92
Registered
2022-01-06
Start date
2022-01-04
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical outcomes of pharmacokinetic and pharmacodynamic meropenem dosing in critically ill patients with sepsis or septic shock is not founded. In addition, Phra Phutthabat Hospital used meropenem in large quantities. meropenem, bacteria infection, mSOFA, sepsis, septic shock

Interventions

Volunteers are received meropenem conventional treatment in patients with sepsis or septic shock,Volunteers are received pharmacokinetic and pharmacodynamic meropenem dosing
Retrospective group,Retrospective group

Sponsors

Silpakorn university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. 18 years and older 2. The patient is diagnosed with sepsis or septic shock who receive meropenem during 72 hours after diagnosis sepsis and 24 hours after diagnosis septic shock. 3. Patients have characteristics at least two of the following. 3.1 Patient is diagnosed with sepsis or SOFA and qSOFA scores greater than or equal 2 points. 3.2 Patient is diagnosed with sepsis shock or received vasopressors or mean arterial pressure less than 65 mm Hg and lactate greater than 2 mmol/L. 3.3 Patient admits to the intensive care unit. 4. Patient founds at least 1 in 4 sources of infection. 4.1 lungs 4.2 Abdominal 4.3 urinary tract 4.4 Blood 5. Patient signs inform consent to participate in prospective study.

Exclusion criteria

Exclusion criteria: 1. Patient is received meropenem for less than 3 days. 2. Patient have a history of receiving meropenem within 1 week prior to recruitment.

Design outcomes

Primary

MeasureTime frame
deltamSOFA score 28 day The mSOFA score combines a clinical assessment of 2 organ systems, cardiovascular system and central nervous system, with laboratory measurements for evaluation of 4 other organ systems.,14 and 28 day mortality 14 and 28 day stay or death

Secondary

MeasureTime frame
Ventilator free day During ICU stay or death or maximun of 28 days Day alive and free of mechanical ventilator,Vasopressor free day During ICU stay or death or maximun of 28 days Day alive and free of vasopressor,ICU free day During ICU stay or death or maximun of 28 days Day alive and not stay in ICU,Hospital free day During ICU stay or death or maximun of 28 days Day alive and not stay in hospital

Countries

Thailand

Contacts

Public ContactSupaporn Kachayangyuen

Silapakorn university

sup_puy_p2@hotmail.com0894957476

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026